Basal cell carcinoma - Mate Pukupuku Pūtau Basal
☆ I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
Ko te mate kiri o te ihu o te tangata kaumātua ka kitea he Mate Pukupuku Pūtau Basal (Basal cell carcinoma). Ko te ihu te waahi ka kitea mo tenei momo mate pukupuku kiri.
Mate Pukupuku Pūtau Basal (Basal cell carcinoma) ka puta mai he taitapa kopikopiko me nga whewhe.
Mate Pukupuku Pūtau Basal (Basal cell carcinoma) ka pohehe he kiritona.
relevance score : -100.0%
ReferencesKo Basal cell carcinoma (BCC) te momo tino mate pukupuku kiri. Ko te whiti o te ra te take matua. Tata ki te katoa o nga keehi BCC e whakaatu ana i te kaha o te Hedgehog tohu i roto i te tātaritanga ngota. He rereke nga maimoatanga e waatea ana me te whiriwhiri i runga i te tupono ka hoki mai ano, te hiranga o te tiaki kiko, te hiahia o te manawanui, me te nui o te mate.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Ko te karakara pūkū kōiwi (Basal cell carcinoma) te momo mate pukupuku kiri e tino kitea ana i roto i ngā pakeke kiri te pakeke 50 neke atu. Kei te piki haere a rātou nama puta noa i te ao, ko te nuinga nā te māramatanga o te rā. Ko ētahi o ngā ahuatanga i ka kaha te tangata ki te whakawhanake i ēnei mate pukupuku i te tamariki. Karakara pūkū kōiwi (Basal cell carcinoma) he rereke te taumahatanga, mai i ngā reinga papapapa, nodular rānei, ka ngawari ki te rongoā ki ngā mea whānui ake e hiahia ana ki te kōrerorero i roto i ngā rōpū rongoā motuhake. Ko te matapētera ka whakawhirinaki ki te hokinga mai o te karakara pūkū kōiwi (Basal cell carcinoma), i tōna kaha ki te tukino i ngā kiko tata. Ko te pokanga te maimoatanga paerewa mō te nuinga o ngā kēhi, me te whakarite kia tika te tango me te iti o te tūpono ka hoki mai anō. Ka taea e ngā tikanga whakaeke iti ake te rongoā i ngā whiu papa.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Ko te maimoatanga tuatahi mō te BCC he surgery. Mō te BCC nui, ka hoki mai anō rānei, inā koa i ngā wāhi tino nui, ka tūtohuhia he micrographically controlled surgery (Mohs surgery). Ko ngā lesion me te BCC iti nui ka whakaaro pea ki ngā maimoatanga kaupapa, ki ngā tikanga kino rānei. He pai te mahi photodynamic therapy mō ngā BCC nodular papapapa me te iti nui. Mō te BCC matatau o te rohe, he metastatic rānei, ka tūtohuhia ngā Hedgehog inhibitors (vismodegib, sonidegib). Mēnā kei te haere tonu te mate, te kāore rānei ki ngā Hedgehog inhibitors, ka taea te whakaaro ki te anti‑PD1 antibody (cemiplimab). He pai te mahi radiotherapy mō ngā lesion kāore e taea te surgery, inā koa ngā lesion pakeke. Ka taea te whakaaro te electrochemotherapy ki te kore te surgery, te radiotherapy rānei.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Ko nga mea morearea ko te rongo ki te rama ultraviolet, te whakamāramatanga iraruke (radiation therapy), te rongo mo te wa roa ki te arsenic me te ngoikore o te mahi a te punaha mate (hei tauira, te whakawhitinga okana). He tino kino te pa ki te rama UV i te wa e tamariki ana.
I muri i te taatai ma te koiora, ko te tikanga ko te maimoatanga ma te tango pokanga. Ka taea tenei ma te tangohanga ngawari mena he iti te mate pukupuku; Mena karekau te mate pukupuku i te iti, ko te nuinga o te waa ka tūtohu kia pokai Mohs.
Ko te mate pukupuku pūtau basal e 32% o nga mate pukupuku katoa o te ao. O nga mate pukupuku kiri i tua atu i te melanoma, tata ki te 80% he mate pukupuku kiri-waa. I roto i te United States, tata ki te 35% o nga tane ma me te 25% o nga wahine ma e pangia ana e te mate pukupuku o te tinana i etahi wa o to ratau oranga.
○ Taatari me te Maimoatanga
#Dermoscopy
#Skin biopsy
#Mohs surgery